Kindred Biosciences, Inc Earning Date (KIN)

USA |NASDAQ |USD

KIN Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 3, 2022 Jun 2022 - - $-0.20
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 3, 2022 Jun 2022 - - $3.54M

Kindred Biosciences, Inc's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.

KIN Earnings Date & History Chart

KIN Earnings & Revenue Forecast

KIN Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 8 $-0.07 $-0.81 $1.22

KIN Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 2 / - $-0.36 $-0.36 $-0.29

KIN Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 8 $53.29M $24.10M $125.00M

KIN Earnings Date & Revenue History

KIN Earnings History

|
Show More
Show More

KIN Revenue History

|
Show More
Show More

Kindred Biosciences, Inc Next Earnings Date & Report

KIN Next Earnings Date & Report Preview: Jun 2022 (FQ)

KIN's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.

Kindred Biosciences, Inc Previous Earnings Dates & Reports

KIN Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Kindred Biosciences, Inc's previous earnings date was May 9, 2022 for its fiscal quarter ended Mar 31, 2022.

KIN Previous Earnings Date & Report Recap: Dec 2020 (FY)

Kindred Biosciences, Inc's previous annual earnings date was Mar 16, 2021 for its fiscal year ended Dec 31, 2020.

KIN's earnings per share (EPS) was $-0.38, beating the consensus analysts forecast of $-0.58 by -35.09% , and higher than the previous year's EPS (Dec 2019) by -76.17%.

Revenues were $42.16M, better than the forecast of $42.15M by 0.03%, and up by 890.70% from previous year's revenue.

The company reported a net income of $-21.80M.

Kindred Biosciences, Inc reported a free cash flow of $-13.49M for its fiscal year, compared to $-64.77M a year ago.

The company ended the fiscal year with $20.44M in total debt, an increase of 2.66% compared to the previous year.